Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib vs chlorambucil in elderly untreated CLL/SLL
CTR20130303Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ibrutinib in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Progression-free survival. Started Jun 2015; status: completed.
02
Drugs
ibrutinib
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on CTR20130303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20130303.